mesylate

(redirected from Mesilate)
Also found in: Dictionary.

mesylate

 [mes´ĭ-lāt]
USAN contraction for methanesulfonate.

mesylate

(mĕs′ə-lāt′)
n.
A salt, ester, or anion of methanesulfonic acid. Also called methanesulfonate.
References in periodicals archive ?
(5) Yoshida T et al., Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
the subject of this public contract is the continuous delivery of the drug osimertinib - mesilate. The contract will be concluded for 48 months.
Kuroda et al., "Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis," Scandinavian Journal of Gastroenterology, vol.
Kim II et al., "Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation," Journal of Korean Medical Science, vol.
Cortelli, "Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats," Clinincal Oral Investigation, vol.
Blood pressure during the hemodialysis period was around 150/80 mmHg using doxazosin mesilate. Under high-dose prednisolone urine volume began to increase at 30th day and he could discontinue hemodialysis at 44th day.
Synthetic molecules such as nafamostat mesilate (NM), gabexate mesilate (GM), and sivelestat sodium hydrate drastically reduced LPS-induced injury at least partly by inhibiting HMGB1 [170-172].
Li, "Preparation and characterization of glutaraldehyde cross-linked O-carboxymethylchitosan microspheres for controlled delivery of pazufloxacin mesilate," International Journal of Biological Macromolecules, vol.
It is reported that nafamostat mesilate (NM), a type of serine protease inhibitor, can attenuate MCAO and reperfusion-induced brain injury via the inhibition of GRP78, CHOP, and phospho-eIF2[alpha] [35].
Efficacy of camostat mesilate compared with famotidine for treatment of functional dyspepsia: is camostat mesilate effective?
Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats.